To investigate the involvement of BRD9 in human leukemia, we first analyzed BRD9 expression levels in 200 clinically annotated AML samples (The Cancer Genome Atlas (TGCA); Ley et al.15), 19 non-transformed human bone marrow progenitor samples (Hematopoietic Stem Cells (HSCs), MultiPotent Progenitors (MPPs), Common Myeloid Progenitors (CMPs), Common Lymphoid Progenitors (CLPs), Granulocyte-Monocyte Progenitors (GMPs), Megakaryocyte-Erythrocyte Progenitors (MEPs)), and 16 differentiated human hematopoietic cell samples (monocytes and macrophages) (Blueprint data set). The gene discussed is BRD9; the disease is cancer.